Business Wire

MN-CAPILLARY-TECH

15.3.2023 14:01:50 CET | Business Wire | Press release

Share
Capillary Named a Leader in Loyalty Technology Solutions Report by Top Independent Research Firm

Capillary Technologies, a customer loyalty SaaS platform, has been named a Leader in “The Forrester WaveTM: Loyalty Technology Solutions, Q1 2023” report. Capillary’s Loyalty+ has earned 5/5 for 13 of the 28 criteria evaluated by Forrester.

The report, authored by Mary Pilecki and Cole Walsh, says that brands continue to invest in loyalty programs and loyalty technology solutions to help them engage and retain consumers — who are cutting back on spending and looking for more deals in response to higher prices. And according to Forrester’s Marketing Survey, 2023, “53% of B2C marketing decision-makers plan to increase their spend on loyalty technology in 2023, and economic uncertainty and scrutiny of marketing budgets has renewed marketers’ focus on the profitability of their loyalty strategies.”

Naming Capillary as a leader, the report states, “Capillary Technologies excels with robust tech capabilities and AI-powered nudges. Capillary Technologies offers a commerce solution, a customer data platform (CDP), and a loyalty platform, and expanded its loyalty reach by acquiring Persuade — a customer experience (CX) technology company — in 2021. Since then, Capillary has enhanced capabilities in its Loyalty+ offering for global clients in APAC, EMEA, and NA.”

In a Wave evaluation where 12 of the most significant vendors were considered, Capillary was evaluated to be one of only three leaders. “For us, this Forrester citation firmly establishes Capillary as a front-runner in the Loyalty Solutions space globally. For more than a decade now, we’ve helped hundreds of large enterprises realize the power of technology in delivering highly efficient loyalty programs to achieve the desired business outcomes. The evaluation in The Forrester Wave as a Leader is, in our opinion, a validation for the hard work the team has put in relentlessly over the years in helping brand marketers achieve extraordinary results and achieve customer loyalty as an outcome,” says Sameer Garde, CEO of Capillary Technologies.

The report further goes on to state, “Loyalty+ outpaces many in this competitive set because of robust functionality and a flexible data model. It excels in both loyalty program management and marketing, as well as in creating actionable insights from both customer and business data. And the platform’s 'nudges' feature leverages AI/ML to give marketers prescriptive advice on everything from program optimization to campaign management.”

About Capillary Technologies: Founded in 2012, Capillary Technologies has a presence across the United States, India, Middle East, and Asia, in particular, Southeast Asia. Capillary Technologies offers end-to-end loyalty programs, a comprehensive view of consumers and unified, cross-channel strategies that deliver a real-time omnichannel, personalized, and consistent experience for customers. Powering a diversified product suite of end-to-end loyalty programs, across 30+ countries, Capillary Technologies works with 250+ brands as of October 30, 2021, including Asics, PUMA, Shell, Tata, Fossil, Hoya, Pantaloons, GKB Opticals, Indian Terrain, Fossil, Vishal Megamart and many more from verticals such as apparel, footwear, supermarkets, conglomerates, manufacturing and electronics, pharmacy and wellness, fine dining and QSR, luxury and jewelry, entertainment, oil and gas, travel and hospitality. With a massive reach of 875 million+ consumers and processing 1.97 billion+ transactions in Fiscal 2021, Capillary Technologies’ promoter i.e., Capillary Technologies International Pte. Ltd. has the backing of Swanland Investment ltd. (an affiliate of Warburg Pincus), Sequoia Capital India Growth Fund II Ltd., Avataar Ventures Partners I, and Filter Capital Fund I Ltd. For more information, visit www.capillarytech.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230315005270/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Alsym Energy Announces Na-Series Battery Success Developed With Physics-Informed AI Platform27.4.2026 21:25:00 CEST | Press release

Alsym’s proprietary physics-informed AI platform powered the development of its Na-Series batteries—a non-flammable, high performance and low cost energy solution positioned to serve critical energy storage markets including data centers, utilities, telecommunications, commercial real estate, industrial and defense, among others. Alsym Energy, a pioneer in non-flammable, high-performance sodium-ion batteries, today announced details of the proprietary physics-informed AI platform used to develop the company’s recently launched Na-Series sodium-ion batteries. By integrating fundamental physics models with AI, autonomous testing and proprietary molecular diagnostics in a closed-loop system, Alsym is accelerating the design of safer, inexpensive, commercialized batteries through all phases of the development cycle. As global demand for electricity surges, the limitations of lithium-ion batteries have become increasingly apparent, particularly around safety and supply chain constraints. Li

Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release

As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi

Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release

Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor

Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release

Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co

Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release

Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye